Articles

• Reliving biotech’s most shocking scandal — the story of Theranos

  The biggest case of fraud in biotech history is getting its day in the spotlight.

• What the FDA’s Plans to Boost Drug Competition Could Mean for Pharma

  The agency is considering various strategies to get pricing under control. But do these ideas factor in critical drug pricing trends?

• The FDA’s Banner Year for Drug Approvals — By the Numbers

  Last year, the FDA once again set a new record for new drug approvals and far surpassed its 10-year average.

• Top Pharma Manufacturing Predictions for 2019

  From new tech to innovative business models and shifting regulations, industry experts weigh in on what changes are coming down the pipeline.